Want to see AU:AVE full AI Analyst Report?
AVE Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.03
Previous CloseN/A
Volume188.16K
Average Volume (3M)3.98M
Market Cap
AU$54.09M
Enterprise ValueAU$82.85M
Total Cash (Recent Filing)AU$6.61M
Total Debt (Recent Filing)AU$227.54K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,863,725,800
10 Day Avg. Volume7,031,930
30 Day Avg. Volume3,983,238
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)18.85
Price to Sales (P/S)23.75
P/FCF Ratio26.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Drug-delivery PlatformA proprietary delivery platform gives Avecho a defined technology base for developing and licensing reformulated medicines. Its ability to address solubility and oral-bioavailability challenges may support differentiated products and create repeatable partnering opportunities across cannabinoid and other therapeutic applications.
Revenue RecoveryThe acceleration in annual revenue growth indicates improving commercial traction after a subdued prior year. If sustained, stronger top-line performance can improve operating leverage, support continued product development, and increase the company’s ability to convert its platform and pipeline into recurring commercial income.
Improved Cash Generation And Low LeveragePositive operating and free cash flow in 2025 materially improves internal funding capacity after several years of cash burn. Combined with very low debt, this gives Avecho greater financial flexibility to pursue development and partnering activity without the immediate burden of substantial interest or refinancing obligations.
Bears Say
Persistent Operating And Net LossesPersistent operating and net losses show that improved revenue has not yet translated into a sustainable earnings model. Continued losses can consume equity, require additional funding, and limit the company’s ability to reinvest in development unless commercial growth becomes sufficiently profitable.
Shrinking Equity BaseA declining equity base indicates that accumulated losses are eroding the financial resources supporting the business. Even with manageable debt, continued deterioration could reduce resilience, constrain investment in the TPM pipeline, and increase dependence on future capital raising or successful commercial milestones.
Volatile Cash-flow ProfileThe sharp shift from recurring cash burn to positive cash flow is encouraging but demonstrates that cash generation has not yet been consistent. If operating needs or working-capital movements reverse the 2025 improvement, Avecho may again need external funding to maintain development and commercialisation activities.
Avecho Biotechnology Limited News
AVE FAQ
What was Avecho Biotechnology Limited’s price range in the past 12 months?
Avecho Biotechnology Limited lowest share price was <AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Avecho Biotechnology Limited’s market cap?
Avecho Biotechnology Limited’s market cap is AU$54.09M.
When is Avecho Biotechnology Limited’s upcoming earnings report date?
Avecho Biotechnology Limited’s upcoming earnings report date is Mar 03, 2027 which is in 127 days.
How were Avecho Biotechnology Limited’s earnings last quarter?
Avecho Biotechnology Limited released its earnings results on Aug 25, 2026. The company reported AU$0 earnings per share for the quarter.
Is Avecho Biotechnology Limited overvalued?
According to Wall Street analysts Avecho Biotechnology Limited’s price is currently Overvalued.
Does Avecho Biotechnology Limited pay dividends?
Avecho Biotechnology Limited does not currently pay dividends.
What is Avecho Biotechnology Limited’s EPS estimate?
Avecho Biotechnology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avecho Biotechnology Limited have?
Avecho Biotechnology Limited has 3,863,725,800 shares outstanding.
What happened to Avecho Biotechnology Limited’s price movement after its last earnings report?
Avecho Biotechnology Limited reported an EPS of AU$0 in its last earnings report. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of Avecho Biotechnology Limited?
Currently, no hedge funds are holding shares in AU:AVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avecho Biotechnology Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AVE Sentiment 87%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-211.39%
Trailing 12-Months
Asset Growth
16.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Technical Analysis
Imugene
―
Paradigm Biopharmaceuticals
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Recce Pharmaceuticals Ltd.
―